2021 CMSC Annual Meeting

Abstracts

Late Breaking-Case Reports/Case Series

Brief Telehealth Screening of MS Patients in the Medical Setting

Background: A significant clinical need exists for a broad range of health care professionals to be able to objectively screen for the...

Read More

Late Breaking-Disease-modifying therapy

The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type

Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic,...

Read More

Late Breaking-Disease-modifying therapy

Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab

Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts...

Read More

Late Breaking-Disease-modifying therapy

Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab

Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in...

Read More

Late Breaking-Epidemiology and genetics

Geographic Variance of MS Prevalence in the United States

Background: The etiology of multiple sclerosis (MS) is not fully understood, and the disease may be triggered or exacerbated by...

Read More

Late Breaking-Psychosocial factors

Connect Trial of Online Professional Support Groups for Black and Latinx People Living with MS

Background: Given the high prevalence of anxiety and depression in MS, many patients struggle to find high quality, professional mental...

Read More

Late Breaking-Neuroimmunology and disease models

Temporal Trends in Humoral and Cellular Immune Responses to Sars-Cov-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated with Natalizumab, Ocrelizumab or Fumarates

Background: Vaccines against SARS-CoV-2 are a key component of public health measures to combat the COVID-19 pandemic. The impact of...

Read More

Late Breaking-Disease-modifying therapy

Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab

Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of...

Read More

Late Breaking-Methods of Care

Evaluating the Impact of Administering Ocrelizumab Via a Home Infusion on Safety and Patient Reported Outcomes

Background: US payers are looking to reduce the cost of administering infusible drugs for multiple sclerosis (MS). Home-based infusion has...

Read More

Late Breaking-Self-care

Patient-Centered Education and Care Coordination Initiative to Improve Self-Management Skills in Latinos with Multiple Sclerosis

Background: Multiple sclerosis (MS) is a chronic, disabling neurological disease that attacks young adults. Similar to many other chronic...

Read More